Cyolo Announces Cyolo PRO: A Hybrid Secure Remote Access Solution for OT Environments
Cyolo, the access company for the digital enterprise, today announced the launch of Cyolo PRO (Privileged Remote Operations), a hybrid secure remote access solution for Operational Technology (OT). Developed specifically to enable safe operations of privileged users, Cyolo PRO is an advanced solution set to redefine Secure Remote Access (SRA) by shifting from managing access to managing operations. Aligning with the core principles of Remote Privileged Access Management (RPAM), Cyolo streamlines access processes providing a hybrid, infrastructure-agnostic solution with a low cost of change. Get Complimentary access to Gartner® report, Securing Remote Privileged Access Management Through RPAM Tools.
"As OT environments change, Cyolo PRO offers a comprehensive set of capabilities tailored to the unique, dynamic needs of organizations operating within these ecosystems. We have been attuned to the requirements emerging from the field, which has driven us to craft a secure, agile, and user-friendly tool,” said Almog Apirion, CEO & Co-founder at Cyolo. “This solution empowers organizations to seamlessly handle remote operations in their core units, without compromising productivity or security."
Cyolo PRO works across environments whether those are cloud-based, cloud-averse or offline. Key features of Cyolo PRO include:
- VPN-less Connectivity with Zero Trust Principles: Cyolo PRO introduces VPN-less connectivity, eliminating the risks associated with network access while adhering to Zero Trust principles.
- Identity Authentication and MFA for Legacy Apps: The solution ensures robust identity authentication, verifying the identity (instead of user) behind the access, even for legacy applications, enhancing overall security measures.
- Granular Access and Actions Management: Cyolo PRO offers granular control over access and actions management using the principles of “least privilege”, providing organizations with a flexible and secure framework.
- Massive Supervision Capabilities: The product includes extensive supervision features and Just in Time access, allowing organizations to monitor and manage remote access effectively.
“Our company has benefited a great deal from Cyolo’s platform,” said Gibson Mark, Senior Systems Administrator at Tata Chemicals. “We’re able to provide seamless remote access to our systems to both internal users and external users. The management overhead of these remote access connections has been greatly reduced. The ease of use of the remote access has been increased for third-party individuals and our internal employees. The adoption rates of these secure remote access methods have gone up substantially since we implemented Cyolo.”
Cyolo PRO is designed to answer the increasing security concerns and complexity around secure remote access in OT environments. Through its solution, Cyolo is empowering organizations with safe, secure and productive remote operations, even in the most demanding mission-critical settings. Its unique capabilities allow organizations to secure access to both internal and third-party users, operating online or offline and in hybrid, on-prem or cloud environments. This comprehensive suite also ensures industry compliance and guarantees uptime, safety and operational integrity.
“With Cyolo PRO’s features, tailored specifically for OT ecosystems, Cyolo is positioning itself as a market leader,” said Joe O’Donnell, Executive Vice President of Corporate Development at Cyolo. “The solution’s capability to seamlessly fit into existing architectures without extensive change management processes is critical in OT environments, as even the slightest change can yield significant consequences.”
Cyolo PRO is now available for enterprises across all critical industries, including manufacturing, oil & gas, utilities, pharmaceuticals, transportation and more. Consolidate your security stack and experience the power of seamless and secure operations across any application in any environment, from legacy infrastructure to cloud environments. Visit https://cyolo.io/ to learn more.
Gartner, Securing Remote Privileged Access Management Through RPAM Tools, Abhyuday Data, Felix Gaehtgens, Michael Kelley, 28 December 2023.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Cyolo
Cyolo is a leading cybersecurity innovator dedicated to providing cutting-edge access solutions for all environments and deployment scenarios. With a focus on security, operational agility, and user experience, Cyolo is fostering a transition from merely enabling access to empowering operations, productivity, and compliance with its Cyolo PRO (Privileged Remote Operations) solution.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304157756/en/
Contact information
Media Contact
10Fold Communications
PR for Cyolo
cyolo@10fold.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
